Canada

Mind Medicine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders

Lead Product(s): Lysergide

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

The company intends to initiate a Phase 2b human efficacy trial that will focus on experiential doses of LSD, administered by a therapist. This is the first experiential, psychedelic-assisted therapy to be added to the company’s drug development pipeline.

Mind Medicine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

Lead Product(s): Lysergide

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

Mind Medicine is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. The clinical trials will add an additional clinical trial site and Principal Investigator at the University Hospital Basel.

Mind Medicine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator

Lead Product(s): Lysergide

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Maastricht University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 12, 2020

Details:

As part of the agreement, Maastricht University will provide facilities and personnel for the Phase 2a Proof of Concept Clinical Trial for MindMed's multicentre trial evaluating the safety and efficacy of low dose LSD as treatment for ADHD in adults.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Mind Medicine

MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders

Mind Medicine

MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

Mind Medicine

MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator